Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
71 recruiting
Showing 1–20 of 125 trials
Recruiting
Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Endometrial Cancer
BioNTech SE480 enrolled171 locationsNCT06340568
Recruiting
Phase 1
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.630 enrolled19 locationsNCT06859762
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled320 locationsNCT06561386
Recruiting
Phase 1
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Solid Tumors, Adult
Grit Biotechnology31 enrolled5 locationsNCT05430373
Recruiting
Phase 1Phase 2
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.105 enrolled30 locationsNCT07367516
Recruiting
Phase 3
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Platinum Resistant Ovarian Cancer
Genmab82 enrolledNCT07604766
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled366 locationsNCT06890598
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled52 locationsNCT07100106
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled419 locationsNCT06119581
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company800 enrolled346 locationsNCT07174336
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic
Eli Lilly and Company150 enrolled50 locationsNCT07218341
Recruiting
Phase 1Phase 2
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.465 enrolled38 locationsNCT07367529
Recruiting
Phase 1Phase 2
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Advanced Solid Tumor
BioNTech SE1,438 enrolled67 locationsNCT07070232
Recruiting
Not Applicable
Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
Breast Cancer SurvivorsEndocrine Therapy-Induced Joint Pain
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine200 enrolledNCT07490938
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled78 locationsNCT07185997
Recruiting
Phase 2
A Phase II Trial of LM103 in Advanced Melanoma
Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.92 enrolled13 locationsNCT07310784
Recruiting
Phase 1
A Phase I Study of JSKN021 in Advanced Solid Tumors
Advanced malignant solid tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd199 enrolled6 locationsNCT07617727
Recruiting
Phase 2
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.120 enrolledNCT07700667
Recruiting
Phase 1Phase 2
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Solid TumorNeuroblastoma
Ascentage Pharma Group Inc.100 enrolled3 locationsNCT05701306